{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-021966","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.766386+00:00","generated_at":"2026-06-24T01:10:16.885929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abeona Q2 net loss $12.1M; cash runway to 2Q 2023; VIITAL data expected late Q3/early Q4","bullets":["Net loss $12.1M ($2.08 loss/share) vs $15.2M ($3.93 loss/share) in Q2 2021.","Cash and investments $26.0M; net cash used in ops $9.0M; runway extended into Q2 2023.","License revenue $1.0M from Taysha sublicense milestone; R&D $6.7M, G&A $3.5M.","Phase 3 VIITAL study for EB-101 topline data expected late Q3/early Q4 2022; last patient monitoring mid-September.","License agreement with Ultragenyx for ABO-102 (MPS IIIA); Abeona eligible for tiered royalties and milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-021966","json":"https://secwatch.observer/filing/0001493152-22-021966.json","markdown":"https://secwatch.observer/filing/0001493152-22-021966.md","text":"https://secwatch.observer/filing/0001493152-22-021966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/0001493152-22-021966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:10:16.885929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}